Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

摘要: We used a sensitive real-time reverse transcription–polymerase chain reaction assay to quantify cyclin D1 mRNA levels in bone marrow samples collected at diagnosis from 74 newly diagnosed multiple myeloma (MM) patients who were randomized undergo either single or double autologous peripheral blood stem cell transplantation as part of first-line therapy for their malignancy. In 46 cases, fluorescence situ hybridization (FISH) analysis and/or conventional cytogenetics performed detect chromosome 11 abnormalities. Patients with the t(11;14) trisomy significantly overexpressed ( P < .0001) comparison without 11q abnormalities, had similar healthy donors. Overall, 32 (43%) showed overexpression. No difference was found between –positive (group A) and –negative B) respect presenting clinical laboratory characteristics, including 13 well response overall survival, both which calculated on an intent-to-treat basis. longer duration remission did not (41 vs 26 months, respectively; = .02). As result, median event-free survival (EFS) group A than B (33 24 .055). concluded that overexpression is closely associated abnormalities identifies subset MM are more likely have prolonged EFS following transplantation.